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The introduction of antiretroviral (ARV) therapy in resource-poor settings is effective in suppressing HIV-1 replication and prolonging life of infected individuals. This has led to a demand for affordable HIV-1 drug resistance assays, since treatment failure due to development of drug resistance is common. This study developed and evaluated an affordable "in-house" genotyping assay to monitor HIV-1 drug resistance in Africa, particularly South Africa. An "in-house" assay using automated RNA extraction, and subtype C specific PCR and sequencing primers was developed and successfully evaluated 396 patient samples (viral load ranges 1000-1.6 million RNA copies/ml). The "in-house" assay was validated by comparing sequence data and drug resistance profiles from 90 patient and 10 external quality control samples to data from the ViroSeq TM HIV-1 Genotyping kit. The "in-house" assay was more efficient, amplifying all 100 samples, compared to 91 samples using Viroseq. The "in house" sequences were 99.2% homologous to the ViroSeq sequences, and identical drug resistance mutation profiles were observed in 96 samples. Furthermore, the "in-house" assay genotyped 260 of 295 samples from seven African sites, where 47% were non-subtype C. Overall, the newly validated "in-house" drug resistance assay is suited for use in Africa as it overcomes the obstacle of subtype diversity.
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to generate an HIV-1 drug resistance report and to determine 169 subtype, as described previously. had viral loads ranging from 2300 to 627,000 RNA copies/ml, indi-
184
cating that primer mismatch in the amplification step rather than 185 a low viral load were likely responsible for lack of amplification.
186
Subtype analysis of these nine sequences generated using the "in-
187
house" assay revealed they were all subtype C. Furthermore, the 188 drug resistance profiles generated for these nine patient samples the specific sequencing primer that failed to amplify using Clustal 208 W ( Fig. 1(a-c) coverage of the region of interest.
217
The "in-house" assay amplified successfully all samples in the
218
VQA panels and the external analysis revealed a high sequence 219 homology compared to sites partaking in the panels. Most impor-220 tantly, the mutation patterns were comparable to the other 221 laboratories partaking in the panels, resulting in the "in-house" 222 assay described here being certified by the NIH VQA.
223
The "in-house" drug resistance assay was evaluated further for 
